After close contact with someone with COVID-19, the next step depends on timing, symptoms and personal risk. Prevention after exposure and treatment of an active infection are different services.
Discover Nao Medical's virtual care solutions for occupational health. From wellness checkups to mental health support, boost productivity with care from anywhere.
Give the office and insurer the exact plan name, member details, clinician, location and purpose of the visit. Ask whether this assessment, each laboratory or imaging service and the medicine have different benefits. Confirm referral and authorization requirements. An approval cannot be promised, and coverage of a visit does not prove coverage of the test or prescription. The clinician reviews the exposure, your health history, pregnancy potential and all medicines. Ask whether the proposed use matches the US label and what to do if symptoms develop. If appropriate, confirm the pharmacy can supply the medicine within the time window. A prescription that arrives after the window is not equivalent to timely prevention.
After close contact with someone with COVID-19, the next step depends on timing, symptoms and personal risk. Prevention after exposure and treatment of an active infection are different services. A consultation reviews the exposure, tests when appropriate and considers whether a preventive prescription fits the current US indication.
Record when the contact occurred and whether you have symptoms or a positive test. Pregnancy and medicine interactions can rule out use. An active infection needs a separate treatment evaluation, particularly for people at higher risk. A prevention request must not delay assessment of symptoms.
The clinician reviews the exposure, your health history, pregnancy potential and all medicines. Ask whether the proposed use matches the US label and what to do if symptoms develop. If appropriate, confirm the pharmacy can supply the medicine within the time window. A prescription that arrives after the window is not equivalent to timely prevention.
Prepare an exact exposure timeline, current test results and a complete medicine and supplement list. Tell the clinician about pregnancy, contraception and breastfeeding. The label requires pregnancy verification before use in people who can become pregnant. Do not withhold relevant medicines or change exposure details to obtain a prescription.
XOCOVA can cause fetal harm and has major drug interactions involving CYP3A and other pathways. Follow clinician and pharmacist advice about contraception and breastfeeding precautions; the label specifies precautions through 2 weeks after treatment. Call 911 for severe breathing difficulty, chest pressure, confusion or inability to stay awake.
Monitor symptoms and follow the clinician's testing and infection-prevention plan. A negative early test does not rule out infection after an exposure. If symptoms or a positive test develop, arrange reassessment for active COVID-19 care. Do not assume the preventive medicine makes you noninfectious.
Confirm appointment capacity, clinician familiarity, exact plan coverage and pharmacy stock immediately because the window is short. A virtual discussion may be feasible, but eligibility and prescribing depend on the actual service and patient location.
No. An office visit benefit does not establish pharmacy coverage for a prescribed medicine. Check the exact drug, formulation, formulary rules, copay and any prior authorization with your pharmacy benefit. Ask the office about visit charges separately; authorization can be denied or delayed.
Ask the selected clinic for a current itemized estimate before the visit. Confirm the consultation fee and separate charges for laboratory tests, imaging, procedures, medicines, forms and follow-up. An older advertised price does not establish today's total or what is included.
Approval is decided by the exact insurance plan and can be delayed or denied. Ask who submits the request and what pharmacy cost applies if it is not approved. Xocova must start within 72 hours of the exposure under its label; an authorization delay does not extend that window. Contact the prescriber promptly if approval or supply may be late.
Seek evaluation promptly after the exposure: Xocova must be started within 72 hours of contact with a person who has COVID-19 under its U.S. label. Insurance authorization, an appointment delay or pharmacy supply does not extend that window. Contact the prescriber immediately if supply or approval may be late so the clinician can reassess the plan. Do not start it outside the prescribed pathway or assume it treats an existing infection.
Choose care according to the problem and how urgently you need help. Urgent care assesses non-emergency illnesses and minor injuries.
